This agrees with encouraging results in the TCL1 AT model, where combination of ibrutinib with either αPD-1 or αPD-L1 considerably improved leukemia control and CD8+ T-cell effector function, with more pronounced effects in the ibrutinib/αPD-L1 combination [105]. This evidence concerns the gene CD8A and leukemia.